Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: Possible association with susceptibility to the disease

Zhang, Yan; Wang, Bo; Ye, Shihui; Liu, Sheng; Liu, Mengli; Shen, Chunmei; Teng, Yan; Qi, Jun

doi:10.1016/j.leukres.2009.04.022

Cited by 39 publications

(32 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although two recent studies reported higher frequency of activating KIR genes, such as KIR2DS1, KIR2DS3 and KIR2DS4 in patients with CML and ALL [22,23], we couldn't reproduce these findings in our cohort. Our findings are thus in agreement with those reported from Babor et al, who also found very similar frequencies of KIR genes among haematological patients and healthy controls with European origin [24].…”

Section: Discussioncontrasting

confidence: 62%

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 62%

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[35][36][37] Since all our 2DS3-positive patients presented also 2DS2, we compared ADCC levels in this combined cohort with 2DS2-positive patients missing 2DS3. Importantly, we did not detect a difference in ADCC levels and EFS between patients with only 2DS2 compared to 2DS2-and 2DS3-positive patients.…”

Section: Discussionmentioning

confidence: 99%

“…Following treatment protocol was used: cytokine IL-2 was given for 5 d (s.c., day 1-5, 6 £ 10 6 IU/m 2 /day), followed by a combined application of IL-2 (s.c., day 8-12, 6 £ 10 6 IU/m 2 / day) with ch14.18/CHO (i.v., day 8-18, 10 mg/m 2 /day) and 13-cis-retinoic acid (p.o., day [22][23][24][25][26][27][28][29][30][31][32][33][34][35]. At initial diagnosis, 46 patients had stage 4, four stage 3, one stage 2 and two stage 1 disease.…”

Section: Patient Characteristicsmentioning

confidence: 99%

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD₂ antibody ch14.18/CHO show higher ADCC levels and improved event-free survival

et al. 2016

View full text Add to dashboard Cite

Polymorphisms in Fc-gamma-receptor (FCGR) genes as well as killer cell immunoglobulin-like receptor (KIR) and KIR ligand (KIRL) repertoires may influence antitumor effects of monoclonal antibodies (mAb). Here, we systematically analyzed high-and low-affinity FCGR2A and -3A genotypes as well as stimulating and inhibitory KIR/KIRL combinations in 53 neuroblastoma (NB) patients treated by long-term infusion (LTI) of anti-GD 2 IgG1 Ab ch14.18/CHO using validated real-time PCR methods.Patients with high-affinity FCGR2A and -3A genotypes showed a higher level of Ab-dependent cellmediated cytotoxicity (ADCC) on day 8 after the start of ch14.18/CHO and superior event-free survival (EFS) compared to patients with low FCGR genotypes. Similar observations were made for patients with stimulatory KIR/KIRL haplotype B (combination of KIR genes including activating receptor genes) compared to inhibitory haplotype A (a fixed set of genes encoding for inhibitory receptors, except 2DS4) and stronger effects were found in patients when haplotype B and high-affinity FCGRs were combined. Surprisingly, independent analysis of KIRs showed a major role of activating KIR 2DS2 for high ADCC levels and prolongation of EFS. The greatest effect was observed in 2DS2-positive patients that also had highaffinity FCGR2A and -3A genotypes.In summary, the presence of the activating KIR 2DS2 has a major effect on ADCC levels and survival in NB patients treated by LTI of ch14.18/CHO and may therefore be a useful biomarker in combination with FCGR polymorphisms for Ab-based immunotherapies.

show abstract

“…Investigation of this region for potential genetic determinants for B-ALL is of great interest because some KIR genes have been shown to be associated with development of certain forms of leukemia in humans. 13 The KIR gene family comprises 14 functional genes. The genes encode synonymous receptors that are expressed mainly on natural killer (NK) cells and regulate their functional activities.…”

Section: Introductionmentioning

confidence: 99%

Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia

Almalte

Samarani

Iannello

et al. 2011

Blood

View full text Add to dashboard Cite

Acute lymphoblastic leukemia of pre-B cells (pre-B ALL) is the most frequent form of leukemia affecting children in Western countries. Evidence is accumulating that genetic factors play an important role in conferring susceptibility/ resistance to leukemia in children. In this regard, activating killer-cell immunoglobulin-like receptor (KIR) genes are of particular interest. Humans may inherit different numbers of the 6 distinct activating KIR genes. Little is known about the impact of this genetic variation on the innate susceptibility or resistance of humans to the development of B-ALL. We addressed this issue by performing a case-control study in Canadian children of white origin. Our results show that harboring activating KIR genes is associated with reduced risk for developing B-ALL in these children. Of the 6 activating KIR genes, KIR2DS2 was maximally associated with decreased risk for the disease (P ‫؍‬ 1.14 ؋ 10 ؊7 ). Furthermore, our results showed that inheritance of a higher number of activating KIR genes was associated with significant reductions in risk for ALL in children. These results were also consistent across different ALL phenotypes, which included children with pre-T cell ALL. Our study provides novel insights concerning the pathogenesis of childhood leukemia in white children and has implications for the development of new immunotherapies for this cancer. (Blood. 2011;118(5): 1323-1328)

show abstract

Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: Possible association with susceptibility to the disease

Cited by 39 publications

References 24 publications

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD₂ antibody ch14.18/CHO show higher ADCC levels and improved event-free survival

Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia

Contact Info

Product

Resources

About

Killer cell immunoglobulin-like receptor gene polymorphisms in patients with leukemia: Possible association with susceptibility to the disease

Cited by 39 publications

References 24 publications

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

Killer Cell Immunoglobulin-Like Receptor Genes Polymorphisms in Macedonian Patients with Haematological Malignancies

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival

Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia

Contact Info

Product

Resources

About

Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD₂ antibody ch14.18/CHO show higher ADCC levels and improved event-free survival